This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
which is the expression for the strain energy density of a Neo-Hookean solid. Several compressible versions of the Gent model have been designed. One such model has the form (the below strain energy function yields a non zero hydrostatic stress at no deformation, refer for compressible Gent models).
== External links == International Chemical Safety Card 0095 NIOSH Pocket Guide to Chemical Hazards. "#0017". National Institute for Occupational Safety and Health (NIOSH). Institut national de recherche et de sécurité (2004). "Alcool allylique". Fiche toxicologique n° 156 (in French). Paris: INRS. State of Michigan public information on allyl alcohol Occupational exposure guidelines
The majority of toxic chemicals found in e-cigarette vapor are below 1% of the corresponding levels permissible by workplace exposure standards, but the threshold limit values for workplace exposure standards are generally much higher than levels considered satisfactory for outdoor air quality. Some chemicals from exposures to the e-cigarette vapor could be higher than workplace exposure standards. A 2018 PHE report stated that the toxicants found in e-cigarette vapor are less than 5% and the majority are less than 1% in comparison with traditional cigarettes. Although several studies have found lower levels of carcinogens in e-cigarette aerosol compared to smoke emitted by traditional cigarettes, the mainstream and second-hand e-cigarette aerosol has been found to contain at least ten chemicals that are on California's Proposition 65 list of chemicals known to cause cancer, birth defects, or other reproductive harm, including acetaldehyde, benzene, cadmium, formaldehyde, isoprene, lead, nickel, nicotine, N-Nitrosonornicotine, and toluene. Free radicals produced from frequent e-cigarette use is estimated to be greater than compared to air pollution. E-cigarette vapor can contain a range of toxicants, and since they have been be used in methods unintended by the producer such as dripping or mixing liquids, this could result in generating greater levels of toxicants.
== Epidemiology == Duchenne muscular dystrophy is the most common type of muscular dystrophy; it affects about one in 5,000 males at birth. Duchenne muscular dystrophy has an incidence of one in 3,600 male infants. In the US, a 2010 study showed a higher amount of those with Duchenne muscular dystrophy age ranging from 5 to 54 who are Hispanic compared to non-Hispanic Whites, and non-Hispanic Blacks.
1993/821) Hinchingbrooke Health Care National Health Service Trust Dissolution Order 1993 (S.I. 1993/822) Hinchingbrooke Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/823) Reconstitution of the Upper Medway Internal Drainage Board Order 1993 (S.I. 1993/824) Reconstitution of the Lower Medway Internal Drainage Board Order 1993 (S.I. 1993/825) National Rivers Authority (Severn-Trent Region) (Reconstitution of the Newark Area Internal Drainage Board) Order 1993 (S.I. 1993/829) Non-Domestic Rates (No.2) (Scotland) Order 1993 (S.I. 1993/830) Medicines (Applications for Manufacturer's and Wholesale Dealer's Licences) Amendment Regulations 1993 (S.I. 1993/832) Medicines (Standard Provisions for Licences and Certificates) Amendment Regulations 1993 (S.I. 1993/833) Medicines Act 1968 (Amendment) Regulations 1993 (S.I. 1993/834) Education (Individual Pupils' Achievements) (Information) (Wales) Regulations 1993 (S.I. 1993/835) Banking Act 1987 (Disclosure of Information) (Specified Persons) (Revocation) Order 1993 (S.I. 1993/836) Education (Grant-maintained Schools) (Finance) (Amendment) Regulations 1993 (S.I. 1993/843) Social Security (Miscellaneous Provisions) Amendment Regulations 1993 (S.I. 1993/846) The Official Secrets Act 1989 (Prescription) (Amendment) Order 1993 (S.I. 1993/847) Local Government (Direct Service Organisations) (Competition) Regulations 1993 (S.I. 1993/848) Calderdale and Kirklees (Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/850) Bolton and Salford (City and Metropolitan Borough Boundaries) Order 1993 (S.I.
Sources: en.wikipedia.org
from arginine via nitric oxide synthase, as a byproduct of the production of nitric oxide for signaling purposes from ornithine through the breakdown of proline or glutamine/glutamate from asymmetric dimethylarginine via DDAH Citrulline is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a byproduct of the reaction catalyzed by NOS family (NOS; EC 1.14.13.39). It is also prevalent in trichohyalin at the inner root sheath and medulla of hair follicles, where it is synthesized from arginine. Arginine is first oxidized into N-hydroxyl-arginine, which is then further converted to citrulline concomitant with release of nitric oxide.
The effects included brightened colors, increased visual contrast, open-eye visuals like colors and patterns, pareidolia, increased significance of objects, enhanced music appreciation, feeling intoxicated, self-analysis, insights, increased body awareness, feelings of joy, happiness, and peacefulness, feeling hyper and energized, feelings of empathy, things feeling ridiculous, humor and laughter, religious feelings, restlessness, social discomfort and avoidance, and nausea, among others. Mescaline was one of Shulgin's "magical half-dozen" psychedelic drugs in PiHKAL. Prominence of color with mescaline is distinctive, appearing brilliant and intense. Recurring visual patterns observed during the mescaline experience include stripes, checkerboards, angular spikes, multicolor dots, and very simple fractals that can turn very complex. The English writer Aldous Huxley described these self-transforming amorphous shapes as like animated stained glass illuminated from light coming through the eyelids in his autobiographical book The Doors of Perception (1954). Like LSD, mescaline induces distortions of form and kaleidoscopic experiences but they manifest more clearly with eyes closed and under low lighting conditions. Heinrich Klüver coined the term "cobweb figure" in the 1920s to describe one of the four form constant geometric visual hallucinations experienced in the early stage of a mescaline trip: "Colored threads running together in a revolving center, the whole similar to a cobweb". The other three are the chessboard design, tunnel, and spiral.
=== Phytochemistry === Natural tobacco polysaccharides, including cellulose, have been shown to be the primary precursors of acetaldehyde in tobacco smoke. The main polyphenols contained in the tobacco leaf are rutin and chlorogenic acid. Amino acids contained include glutamic acids, asparagine, glutamine, and γ-Aminobutyric acid. Pyridine alkaloids are present in tobacco as free bases and salts. Nicotine accounts for 90–95% of the plant's pyridines with nornicotine and anatabine accounting for roughly 2.5% each. Pyridyl functional groups present in minute amounts include anabasine, myosmine, cotinine and 2, 3′-bipyridyl. Indole alkaloids are also present in leaves and stems which includes harmala alkaloids as well. Yohimbine, harmine, harmaline and ajmalicine occurs in descending order, yohimbine being highest. The tobacco plant readily absorbs heavy metals from the surrounding soil and accumulates them in its leaves. These are readily absorbed into the user's body following smoke inhalation. Tobacco also contains the following phytochemicals: glucosides (tabacinine, tabacine), 2,3,6-trimethyl-1,4-naphthoquinone, 2-methylquinone, 2-Naphthylamine, propionic acid, anthalin, anethole, acrolein, cembrene, choline, nicotelline, nicotianine, and pyrene.
Dry ice is the solid form of carbon dioxide (CO2), a molecule consisting of a single carbon atom bonded to two oxygen atoms. Dry ice is colorless, odorless, and non-flammable, and can lower the pH of a solution when dissolved in water, forming carbonic acid (H2CO3). At pressures below 5.13 atm and temperatures below −56.4 °C (216.8 K; −69.5 °F) (the triple point), CO2 changes from a solid to a gas with no intervening liquid form, through a process called sublimation. The opposite process is called deposition, where CO2 changes from the gas to solid phase (dry ice). At atmospheric pressure, sublimation/deposition occurs at 194.7 K (−78.5 °C; −109.2 °F). The density of dry ice increases with decreasing temperature and ranges between about 1.55 and 1.7 g/cm3 (97 and 106 lb/cu ft) below 195 K (−78 °C; −109 °F). The low temperature and direct sublimation to a gas makes dry ice an effective coolant, since it is colder than water ice and leaves no residue as it changes state. Its enthalpy of sublimation is 571 kJ/kg (25.2 kJ/mol, 136.5 calorie/g). Dry ice is non-polar, with a dipole moment of zero, so attractive intermolecular van der Waals forces operate. The composition results in low thermal and electrical conductivity.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.